An objective and validated index of nausea and vomiting such as the Pregnancy-Unique Quantification of Emesis (PUQE) and HyperEmesis Level Prediction (HELP) tools can be used to classify the severity of NVP and HG. [Grade C] Ketonuria is not an indicator of dehydration and should not be used to assess severity. [Grade A] There are safety and efficacy data for first line antiemetics such as anti (H1) histamines, phenothiazines and doxylamine/pyridoxine (Xonvea®) and they should be prescribed initially when required for NVP and HG (Appendix III). [Grade A] There is evidence that ondansetron is safe and effective. Its use as a second line antiemetic should not be discouraged if first line antiemetics are ineffective. Women can be reassured regarding a very small increase in the absolute risk of orofacial clefting with ondansetron use in the first trimester, which should be balanced with the risks of poorly managed HG. [Grade B] Metoclopramide is safe and effective and can be used alone or in combination with other antiemetics. [Grade B] Because of the risk of extrapyramidal effects metoclopramide should be used as second-line therapy. Intravenous doses should be administered by slow bolus injection over at least 3 minutes to help minimise these. [Grade C] Women should be asked about previous adverse reactions to antiemetic therapies. If adverse reactions occur, there should be prompt cessation of the medications. [GPP] Normal saline (0.9% NaCl) with additional potassium chloride in each bag, with administration guided by daily monitoring of electrolytes, is the most appropriate intravenous hydration. [Grade C] Combinations of different drugs should be used in women who do not respond to a single antiemetic. Suggested antiemetics for UK use are given in Appendix III. [GPP] Thiamine supplementation (either oral 100 mg tds or intravenous as part of vitamin B complex (Pabrinex®)) should be given to all women admitted with vomiting, or severely reduced dietary intake, especially before administration of dextrose or parenteral nutrition. [Grade D] All therapeutic measures should have been tried before considering termination of pregnancy. [Grade C].
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/1471-0528.17739 | DOI Listing |
Breast Cancer Res Treat
January 2025
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Pain Med
January 2025
IRCCS IstitutoOrtopedico Galeazzi, Unit of Clinical Epidemiology, Milan, Italy.
Objective: To assess the effectiveness of cognitive functional therapy (CFT) in reducing disability and pain compared to other interventions in chronic spinal pain patients.
Methods: Five databases were queried to October 2023 for retrieving randomized controlled trials (RCTs), including patients with chronic spinal pain and administering CFT. Primary outcomes were disability and pain.
Integr Cancer Ther
January 2025
Guang 'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Pak J Pharm Sci
January 2025
Clinical Pharmacy Department, Hiwa Cancer Hospital, Sulaymaniyah, Iraq.
Hematological toxicity is a predominant concern encountered during cancer treatment. Regular blood tests and follow-up are crucial for cancer patients. The objective of this study was to evaluate and compare the hematological toxicities seen by breast cancer patients who were administered paclitaxel during treatment cycles.
View Article and Find Full Text PDFPilot Feasibility Stud
January 2025
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!